ProCE Banner Activity

Expert View on Managing Patients With CLL Using Targeted Therapies

Slideset Download
Download these slides to review the most recent clinical data on targeted therapies in both frontline and relapsed/refractory CLL.

Released: February 14, 2020

Expiration: February 12, 2021

No longer available for credit.

Share

Faculty

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Pharmacyclics AbbVie

Verastem Oncology

Partners

CLL Society

ProCE Banner

Faculty Disclosure

Primary Author

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead, Pharmacyclics, and Sunesis.

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, Acerta, AstraZeneca, BeiGene, Genentech, Gilead, Pharmacyclics, and Sunesis.